Zydus Cadila has received the final approval from the USFDA to market Pindolol Tablets USP, 5 mg and 10 mg. Pindolol belongs to a class of medication called beta-blockers and is used to treat hypertension.

The drug will be manufactured at the group's formulations manufacturing facility at the Pharma SEZ, Ahmedabad. The sale of Pindolol tablets is estimated at USD 83.59 million. Source: 1MS Health, IMS National Sales Perspective Audit. MAT June 2017, extracted August 2017.
 
The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company declined Rs 3.3, or 0.7%, to trade at Rs 469.75. The total volume of shares traded was 13,323 at the BSE (10.49 a.m., Tuesday).